SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...

Artificial intelligence (AI) is rapidly transforming clinical trials by dramatically reducing timelines and costs, accelerating patient-centered drug development and creating more resilient and ...

Findings from a randomized and blinded clinical trial investigating repeated ketamine infusions for treating depression have ...

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory ...

SCYNEXIS Inc. (NASDAQ: SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative ...

Natera (NTRA) announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer. The ...

(RTTNews) - Quantum BioPharma Ltd. (QNTM), Tuesday announced that the company has received the clinical study report for the phase 1 multiple ascending dose trial of experimental multiple sclerosis ...

Data from the Phase Ia/b study demonstrated that SAT-3247 was well-tolerated and safe with a desirable PK profile.

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

The termination of thousands of federal grants that fund clinical trials threatens to reverse substantial progress in ...